Estradiol-Receptor Blockade in Older Men and Women
Study Details
Study Description
Brief Summary
Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Systemic concentrations of Te, E2, GH, IGF-I and insulin growth factor binding protein 3 (IGFBP-3) decline in healthy aging men and women. Relative sex-steroid deprivation accentuates GH and IGF-I depletion, since Te stimulates GH and IGF-I production in older men, hypogonadal males of all ages, and patients undergoing (genotypic female-to-male) gender reassignment. The estrogen-receptor antagonist, tamoxifen, blocks this effect of Te, suggesting involvement of E2 in GH's stimulation at least in young men. E2 alone stimulates GH secretion in young and older women. Because Te is converted to E2 by aromatization in the body, we postulate that E2 is the active moiety in both men and women. Moreover, we hypothesize that the decline of E2 in older men and women contributes to the fall in GH output. These basic concepts will be tested here.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Oral Toremifene/Oral Placebo Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit. After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit. |
Drug: Toremifene
Drug: Placebo
Drug: GHRH/Ghrelin combined Injection
|
| Experimental: Oral Placebo/Oral Toremifene Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit. After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit. |
Drug: Toremifene
Drug: Placebo
Drug: GHRH/Ghrelin combined Injection
|
Outcome Measures
Primary Outcome Measures
- Summed mass of growth hormone over 10 hours [Participants will be followed for an average of 2 months with growth hormone measurements occuring 10 days after initiating study medication administration.]
Subjects will be given toremifene/placebo on Day 1 to take for 10 days. For one night between Days 8-12, from date of randomization, subjects will undergo a 12-h overnight (2200-1000h) fasting, every 10-min blood sampling. The primary analytical outcome is the summed mass of growth hormone (ie. mean/min/max) secreted in pulses over the first 10h of overnight blood samples. Pulsatile growth hormone is relevant, since sex-steroid hormones and regulatory peptides uniquely control growth hormone secretory-burst mass
Secondary Outcome Measures
- Growth hormone responsiveness over last 2h [Participants will be followed for an average of 2 months with growth hormone measurements occuring 10 days after initiating study medication administration]
Subjects will be given toremifene/placebo on Day 1 to take for 10 days. For one night between Days 8-12, from date of randomization, subjects will undergo a 12-h overnight (2200-1000h) fasting, every 10-min blood sampling. The secondary analytical outcome is growth hormone responsiveness over the last 2 hours to bolus GHRH/ghrelin stimulation (ie. mean/min/max).
Eligibility Criteria
Criteria
Inclusion:
-
40 healthy women and men (ages 50 to 80 y); women will be post-menopausal (clinically defined by E2 < 50 pg/mL, FSH > 30Iu/L)
-
BMI 18-35 kg/m2
-
community dwelling; and voluntarily consenting
Exclusion:
-
recent use of psychotropic or neuroactive drugs (within five biological half-live);
-
obesity (outside weight range above);
-
Laboratory test results not deemed physician acceptable, viz potassium <3.5 mEq/L, magnesium <1.5 mEq/L, triglycerides > 300, BUN >30 or creatinine > 1.5 mg/dL, liver functions tests twice upper limit of normal, anemia (hemoglobin must meet Blood Bank requirements - Hgb ≥ 12.5 g/dL)
-
drug or alcohol abuse, psychosis, depression, mania or severe anxiety;
-
acute or chronic organ-system disease, including renal failure (creatinine > 1.5 mg/dL)
-
endocrinopathy, other than primary thyroidal failure receiving replacement
-
nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission),
-
acute weight change (loss or gain of > 2 kg in 6 weeks);
-
allergy to toremifene
-
unwillingness to provide written informed consent.
-
PSA > 4.0 ng/mL in men
-
History or suspicion of prostatic disease (elevated PSA, indeterminate nodule or mass, obstructive uropathy, or breast cancer),
-
Other carcinoma (excluding localized basal cell carcinoma removed or surgically treated with no recurrence).
-
History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep vein thrombophlebitis.
-
History of CHF, cardiac arrhythmias, congenital QT prolongation, and medications used to treat cardiac arrhythmias or other strong CYP3A4 inhibitors.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: Johannes Veldhuis, MD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 14-004704